

HR 4209

Patients' Access to Treatments Act of 2012

Congress: 112 (2011–2013, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 19, 2012

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Mar 19, 2012)

Official Text: <https://www.congress.gov/bill/112th-congress/house-bill/4209>

Sponsor

Name: Rep. McKinley, David B. [R-WV-1]

Party: Republican • **State:** WV • **Chamber:** House

Cosponsors (43 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Capps, Lois [D-CA-23]	D · CA		Mar 19, 2012
Rep. Cuellar, Henry [D-TX-28]	D · TX		Mar 19, 2012
Rep. Frank, Barney [D-MA-4]	D · MA		Mar 19, 2012
Rep. Young, C. W. Bill [R-FL-10]	R · FL		Mar 19, 2012
Rep. Harper, Gregg [R-MS-3]	R · MS		Mar 28, 2012
Rep. Conyers, John, Jr. [D-MI-14]	D · MI		Apr 16, 2012
Rep. McGovern, James P. [D-MA-3]	D · MA		Apr 16, 2012
Rep. Bartlett, Roscoe G. [R-MD-6]	R · MD		Apr 19, 2012
Rep. Deutch, Theodore E. [D-FL-19]	D · FL		Apr 19, 2012
Rep. Farr, Sam [D-CA-17]	D · CA		Apr 19, 2012
Rep. Rothman, Steven R. [D-NJ-9]	D · NJ		Apr 19, 2012
Rep. Bonner, Jo [R-AL-1]	R · AL		Apr 24, 2012
Rep. Crenshaw, Ander [R-FL-4]	R · FL		Apr 24, 2012
Rep. Jackson, Jesse L., Jr. [D-IL-2]	D · IL		Apr 24, 2012
Rep. Bachus, Spencer [R-AL-6]	R · AL		May 9, 2012
Rep. Langevin, James R. [D-RI-2]	D · RI		May 9, 2012
Rep. Pingree, Chellie [D-ME-1]	D · ME		May 9, 2012
Rep. Roybal-Allard, Lucille [D-CA-34]	D · CA		May 9, 2012
Rep. Tonko, Paul [D-NY-21]	D · NY		May 9, 2012
Rep. Young, Don [R-AK-At Large]	R · AK		May 9, 2012
Rep. Cicilline, David N. [D-RI-1]	D · RI		Jun 5, 2012
Rep. Moran, James P. [D-VA-8]	D · VA		Jun 7, 2012
Rep. Davis, Susan A. [D-CA-53]	D · CA		Jul 19, 2012
Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4]	D · GA		Jul 19, 2012
Rep. Boswell, Leonard L. [D-IA-3]	D · IA		Sep 12, 2012
Rep. Courtney, Joe [D-CT-2]	D · CT		Sep 12, 2012
Rep. Gerlach, Jim [R-PA-6]	R · PA		Sep 12, 2012
Rep. Holt, Rush [D-NJ-12]	D · NJ		Sep 12, 2012
Rep. Michaud, Michael H. [D-ME-2]	D · ME		Sep 12, 2012
Rep. Pastor, Ed [D-AZ-4]	D · AZ		Sep 12, 2012
Rep. Rangel, Charles B. [D-NY-15]	D · NY		Sep 12, 2012
Rep. Runyan, Jon [R-NJ-3]	R · NJ		Sep 12, 2012
Rep. Wolf, Frank R. [R-VA-10]	R · VA		Sep 12, 2012
Rep. Woolsey, Lynn C. [D-CA-6]	D · CA		Sep 12, 2012
Rep. Capito, Shelley Moore [R-WV-2]	R · WV		Sep 20, 2012
Rep. Davis, Danny K. [D-IL-7]	D · IL		Sep 20, 2012
Rep. Markey, Edward J. [D-MA-7]	D · MA		Sep 20, 2012
Rep. Towns, Edolphus [D-NY-10]	D · NY		Sep 20, 2012
Rep. Bishop, Timothy H. [D-NY-1]	D · NY		Sep 21, 2012
Rep. Bonamici, Suzanne [D-OR-1]	D · OR		Sep 21, 2012
Rep. McDermott, Jim [D-WA-7]	D · WA		Nov 30, 2012

Cosponsor	Party / State	Role	Date Joined
Rep. Welch, Peter [D-VT-At Large]	D · VT		Dec 11, 2012
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Dec 12, 2012

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Mar 19, 2012

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Mar 19, 2012)

Patients' Access to Treatments Act of 2012 - Amends the Public Health Service Act to prohibit a health plan offering group or individual health insurance that provides coverage for prescription drugs and uses a formulary or other tiered cost-sharing structure from imposing co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier that exceed the dollar amount of such requirements applicable to prescription drugs in a non-preferred brand drug tier.

Provides that if a formulary used by such a health plan contains more than one non-preferred brand drug tier, such prohibition shall be applied with respect to the non-preferred brand drug tier for which beneficiary cost-sharing is lowest.

Defines: (1) "non-preferred brand drug tier" as a category of drugs within a tier in such formulary for which beneficiary cost-sharing is greater than tiers for generic drugs or preferred brand drugs in the plan's formulary, that are prescription drugs, and that are not included within a specialty drug tier; and (2) "specialty drug tier" as a category of drugs within a tier in such formulary for which beneficiary cost-sharing is greater than tiers for generic drugs, preferred brand drugs, or non-preferred drugs in the plan's formulary and that are prescription drugs.

Actions Timeline

- **Mar 19, 2012:** Introduced in House
- **Mar 19, 2012:** Referred to the House Committee on Energy and Commerce.

LegiList

CONGRESS, MADE CLEAR.

Search Every Federal Bill, Law, and Vote

LegiList is the fastest way to research Congress. Track any bill from introduction to enactment, see how every legislator voted, follow committee activity, and read the full text of every bill — all in one place, always up to date.

legilist.com

Free Course: Learn How Congress Actually Works

LegiList Learn is a free, self-paced course that walks through the entire legislative process — from drafting a bill to a presidential signature. Seven modules, plain language, no politics. Earn a certificate when you finish.

legilist.com/learn

Developer API: Build Apps on Legislative Data

The LegiList API gives developers direct access to bills, votes, legislators, committees, and more. Start free with 1,000 requests per day — no credit card required. Upgrade to Pro when you need to scale.

legilist.com/api

Public data belongs to the public. — legilist.com